Medical Condition News

RSS

Proteinuria, a long accepted indicator of heart disease risk, has less impact on African-Americans compared to whites

The cardiovascular risk that is associated with proteinuria, or high levels of protein in the urine, a common test used by doctors as an indicator of increased risk for progressive kidney disease, heart attack and stroke, has race-dependent effects, according to a new study by researchers at Wake Forest University School of Medicine.

12 Jan 2010

YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration

YM BioSciences Inc. today announced results of a collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The approach has successfully concluded its first series of proof-of-principle experiments establishing promise for future development and application.

12 Jan 2010

GSK exercises option to obtain exclusive license to develop and commercialize Traficet-EN

GlaxoSmithKline (GSK) and ChemoCentryx, Inc. today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease.

12 Jan 2010

University of Haifa receives grant to investigate role of protein expression in memory formation

Prof. Kobi Rosenblum, Head of the Department of Neurobiology and Ethology at the University of Haifa, has been awarded a -1.6 million grant from DIP, a German-Israeli Project Cooperation, over a five-year period. This grant will fund Prof. Rosenblum's international research of the role of protein expression in memory formation and stability.

12 Jan 2010

Pfizer commences SBI-087 Phase 2 clinical trial for RA

Trubion Pharmaceuticals, Inc. today announced that its collaboration partner, Pfizer, has initiated a Phase 2 clinical trial of SBI-087 (PF-05230895) for the treatment of rheumatoid arthritis (RA). SBI-087 is a next-generation, humanized Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic directed against the CD20 antigen. SBI-087 is also being evaluated in Phase 1 clinical trials for RA and systemic lupus erythematosus (SLE).

12 Jan 2010

Cancer drug may provide an effective secondary treatment for gut tumor

A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract, according to a team led by researchers from the University of Pittsburgh Cancer Institute (UPCI). The findings, based on experiments using cell cultures, were published in the Jan. 1 issue of Cancer Research.

12 Jan 2010

Researchers discover new ways for treatment of cancer

Researchers at the Swedish medical university Karolinska Institutet have discovered a new way of blocking the formation of blood vessels and halting the growth of tumours in mice. A substance that exploits this mechanism could be developed into a new treatment for cancer.

12 Jan 2010

New therapeutic treatment may provide a potential alternative to bone grafting operation

A study published this week reinforces the potential value of stem cells in repairing major injuries involving the loss of bone structure.

12 Jan 2010

Interim results from Phase I clinical trials utilizing PLX-PAD for treatment of CLI reported

Pluristem Therapeutics Inc. today announced interim results from their Phase I clinical trials utilizing their placenta derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

12 Jan 2010

BioMarin Pharmaceutical commences BMN 195 Phase 1 clinical study for DMD

BioMarin Pharmaceutical Inc. announced today that the first subject has initiated treatment in the Phase 1 clinical study of BMN 195, a small molecule utrophin upregulator, for the treatment of Duchenne muscular dystrohpy (DMD). Initial top-line results are expected in the third quarter of 2010.

12 Jan 2010

Study demonstrates benefits of allergen immunotherapy for children with allergic rhinitis

Allergy immunotherapy, generally referred to as allergy vaccinations or shots, reduce total health care costs in children with allergic rhinitis (hay fever) by one-third, and prescription costs by 16 percent, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).

11 Jan 2010

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Sangamo BioSciences, Inc. announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Juvenile Diabetes Research Foundation International (JDRF).

11 Jan 2010

Targacept signs collaboration and license agreement with AstraZeneca

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced that its collaboration and license agreement with AstraZeneca for the global development and commercialization of TC-5214 for major depressive disorder (MDD) has become effective as a result of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

11 Jan 2010

Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today announced that first patients were enrolled in the MARINE and ANCHOR Phase 3 clinical trials for AMR101, the Company's lead product candidate. These clinical trials are designed to demonstrate that AMR101 lowers triglyceride levels in patients with very high triglycerides (the MARINE Study) and high triglycerides in patients with mixed dyslipidemia being treated with statins (the ANCHOR Study).

11 Jan 2010

NIH renews grant to continue cell growth regulation research

The new year began on a high note for Alan Leonard and Julia Grimwade, professors of biological sciences at Florida Institute of Technology, when they learned their National Institutes of Health grant, which they have held for the last 11 years, had been renewed for four more years. The competitive renewal brings them $1,024, 944 to continue their research into the regulation of cell growth and division.

11 Jan 2010

Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published

Raptor Pharmaceutical Corp. ("Raptor" or the "Company"), today announced the publication of results from a Phase 2a clinical trial of a prototype formulation of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

11 Jan 2010

New technique may help researchers to test amyloid hypothesis in AD development

Current Alzheimer's disease (AD) research indicates that accumulation of amyloid-beta (Aβ) protein plaques in the brain is central to the development of AD.

11 Jan 2010

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Mirna Therapeutics announced today that the Company received a $5 million award from the State of Texas through the Texas Emerging Technology Fund (“ETF”). The ETF was created with the goal of growing new and existing businesses to accelerate the introduction of new products and services in the marketplace. This is the largest award of this type that has ever been granted.

11 Jan 2010

Meda receives exclusive rights to distribute AML drug in Europe and Asia

Meda has in-licensed exclusive rights to Ceplene (histamine dihydrochloride) from EpiCept Corporation, a US-based biopharmaceutical company.

11 Jan 2010

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

Medical Condition News

Proteinuria, a long accepted indicator of heart disease risk, has less impact on African-Americans compared to whites

YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration

GSK exercises option to obtain exclusive license to develop and commercialize Traficet-EN

University of Haifa receives grant to investigate role of protein expression in memory formation

Pfizer commences SBI-087 Phase 2 clinical trial for RA

Cancer drug may provide an effective secondary treatment for gut tumor

Researchers discover new ways for treatment of cancer

New therapeutic treatment may provide a potential alternative to bone grafting operation

Interim results from Phase I clinical trials utilizing PLX-PAD for treatment of CLI reported

BioMarin Pharmaceutical commences BMN 195 Phase 1 clinical study for DMD

Study demonstrates benefits of allergen immunotherapy for children with allergic rhinitis

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Targacept signs collaboration and license agreement with AstraZeneca

Amarin commences enrollment in its AMR101 Phase 3 clinical trials for cardiovascular disease

NIH renews grant to continue cell growth regulation research

Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published

New technique may help researchers to test amyloid hypothesis in AD development

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Meda receives exclusive rights to distribute AML drug in Europe and Asia

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News